Cabazitaxel Liquid Formulation Nanodispersion Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cabazitaxel formulations are physically unstable, require multiple dilutions, and have limited storage stability, making them unsuitable for convenient and stable intravenous administration.
Innovation Solution
A stable, single-vial liquid formulation of cabazitaxel is developed, comprising cabazitaxel, polyethylene glycol 400, ethanol, citric acid, and macrogol 15 hydroxy stearate, which forms a nanodispersion with nanoparticles less than 500 nm, enhancing stability and allowing direct dilution for parenteral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If cabazitaxel is formulated in conventional aqueous solutions, then the formulation is simple to prepare, but the drug exhibits poor solubility and physical instability
Solution Approach 1:
The patent changes the physical-chemical parameters of the formulation by using co-solvent systems (ethanol/polyethylene glycol 400/citric acid) instead of conventional aqueous solutions, achieving both improved solubility (10-100 mg/mL) and enhanced physical stability through controlled nanoparticle formation
Solution Approach 2:
The formulation employs a composite solvent system combining ethanol, polyethylene glycol 400, and citric acid, along with surfactants like macrogol 15 hydroxy stearate, to create a stable nanodispersion that simultaneously addresses solubility and stability requirements
2Ease of operation
If multiple dilutions are required for administration, then the formulation can achieve appropriate dosage, but the process increases complexity and risk of crystallization
Solution Approach 1:
The formulation is pre-prepared as a stable concentrate with optimized solubility characteristics, allowing direct single-vial dilution for infusion without requiring multiple sequential dilutions, thereby reducing operational complexity and crystallization risk
3Stability of the object's composition
If conventional formulations are stored at ambient conditions, then storage is convenient, but storage stability is limited
Solution Approach 1:
The formulation uses an inert co-solvent system based on ethanol and polyethylene glycol 400 that creates a chemically stable environment resistant to degradation, enabling long-term storage stability at ambient temperatures without requiring specialized storage conditions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation provides enhanced storage stability for at least one year at ambient conditions and allows for efficient, single-vial administration, reducing the risk of crystallization and improving drug delivery to target tissues.
Implementation Method 1
which forms a nanodispersion with nanoparticles less than 500 nm, enhancing stability
Implementation Method 2
cabazitaxel and at least one solubilizer dissolved in alcoholic solvents
Implementation Method 3
reducing the risk of crystallization and improving drug delivery to target tissues
Data Source
AI summary
The present invention relates to a stable liquid formulation of cabazitaxel. The formulation comprises cabazitaxel, and at least one solubilizer. Typically, formulations are in the form of ready-to-use solutions or concentrates.